Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Supplement—October 2024
SUPPLEMENT ISSUE
Articles

Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance

Lindsay C. Morton1Comments to Author , Nazia Rahman1, and Kimberly A. Bishop-Lilly1
Author affiliation: Cherokee Nation Strategic Programs, Tulsa, Oklahoma, USA (L.C. Morton, N. Rahman); Global Emerging Infections Surveillance Branch, Silver Spring, Maryland, USA (L.C. Morton, N. Rahman); Naval Medical Research Command Biological Defense Research Directorate, Fort Detrick, Maryland, USA (K.A. Bishop-Lilly)

Main Article

Table

Global Emerging Infections Surveillance program strategic activities for developing and maintaining genomic surveillance capabilities

Strategy Description Benefits
Consortium
Forming a group of NGS and bioinformatics subject-matter experts and well-established DoD laboratory partners led by an experienced program office
Ensures that genomic surveillance remains a priority for DoD
Tiered framework
Development of a 3-tiered strategic framework for public health investments in sequencing and bioinformatics within DoD
Prioritizes limited resources to maintain (or expand) genomic surveillance capabilities
Coordination meetings
Regular meetings for GEIS program, DoD, and non-DoD stakeholders
Provides better coordination across a diverse set of stakeholders
Funding
Leveraging diverse DoD and US government funding streams from public health to biodefense, biosecurity, and pandemic response(s)
Maintains genomic surveillance capabilities
Routine assessments
Continuous assessment of NGS and bioinformatics capabilities through a variety of assessment tools (e.g., site visits, structured/unstructured surveys, and proficiency testing exercises)
Provides “ground truth” or validation of capabilities
Appropriate interventions
Deployment of interventions (e.g., equipment, protocols, training, and reach back testing) to address identified gaps
Maintains genomic surveillance capabilities and equipment/personnel readiness
Tracking products
Tracking of genomic surveillance products (e.g., genomes produced/shared, publications, presentations, protocols developed, and technical assistance provided)
Demonstrates return on investments in genomic surveillance and potential effects on public health
Communication with leadership Providing senior leadership with regular updates on findings and impacts from genomic surveillance Improves public health decision-making

*DoD, Department of Defense; GEIS, Global Emerging Infections Surveillance; NGS, next-generation sequencing.

Main Article

1These authors contributed equally to this article.

Page created: October 30, 2024
Page updated: November 11, 2024
Page reviewed: November 11, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external